(Press-News.org) Semaglutide effectively treats liver disease in two thirds of patients, new research has found.
Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of Medicine shows treating patients with the substance can halt and even reverse the disease.
The placebo-controlled outcome trial of participants with a life-threatening form of liver disease known as Metabolic dysfunction associated steatohepatitis (MASH) was conducted at 253 clinical sites across 37 countries around the world. This is the first regulatory-level trial showing the benefit of semaglutide for people with MASH.
The trial is led by two Chief Investigators, Professor Philip Newsome at King’s College London and Arun Sanyal at the VCU School of Medicine, United States, and funded by Novo Nordisk.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a long-lasting liver condition caused by having too much fat in the liver. MASH is a more severe form of MASLD. It is closely linked with obesity as well as conditions such as type 2 diabetes and heart and circulatory disease. Over time, the build-up of fat in the liver can lead to inflammation, liver fibrosis, cirrhosis and liver cancer. MASLD affects 1 in 5 people in the UK but there are no medicines licensed to specifically treat the disease.
Researchers chose to investigate semaglutide as a potential treatment because this class of drug helps reduce fat and liver scarring for people with MASH. Previous smaller but positive studies by Professor Newsome, published in the Lancet and NEJM, had shown using semaglutide as a treatment for MASH would have benefit for these patients.
Between May 27, 2021 and April 18, 2023, 800 participants were randomly assigned to receive once-weekly injection of 2.4milligrams of semaglutide or placebo, alongside lifestyle counselling. More than half of participants had type 2 diabetes and approximately three-quarters were living with obesity.
Results from the ESSENCE trials after 72 weeks of treatment found 62.9% of participants experienced a reduction in steatohepatitis (inflammation of the liver with fat accumulation in the liver) versus 34.3% for participants who took the placebo. The results also show 36.8% of the semaglutide group had improvements of their liver fibrosis versus 22.4% in the placebo group. Researchers also found other benefits. Those receiving semaglutide also saw improvements in liver enzymes and other blood measures of liver fibrosis, as well as 10.5% weight loss. Gastrointestinal adverse events were more common in the semaglutide group, such as nausea, diarrhea, constipation, and vomiting.
Professor Philip Newsome, Director of the Roger Williams Institute of Liver Studies at King’s College London, said: “I’ve been working with GLP-1 treatments for sixteen years and these results are hugely exciting. MASLD is a growing problem worldwide and this trial will provide real hope for patients with MASH. While these results must be treated with caution, the analysis shows semaglutide can be an effective tool to treat this advanced liver disease.”
The research team will close to 1,200 participants from 37 countries for up to five years to gather data on semaglutide’s impact on long-term liver complications.
Read the paper Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis in the New England Journal of Medicine.
ENDS
END
Semaglutide treats liver disease in two thirds of patients
2025-04-30
ELSE PRESS RELEASES FROM THIS DATE:
Gene therapy restores immune function and extends lives of children with rare immune disorder
2025-04-30
An investigational gene therapy has successfully restored immune function in all nine children treated with the rare and life-threatening immune disorder called severe leukocyte adhesion deficiency-I, or LAD-I, in an international clinical trial co-led by UCLA.
LAD-I is a genetic condition that affects approximately one in a million people in the world. It is caused by mutations in the gene that produces CD18, a protein that enables white blood cells to travel from the bloodstream to infection sites. In the absence of this critical protein, individuals with severe LAD-I — most of whom are diagnosed within ...
VCU-led research highlights semaglutide’s potential for treating fatty liver disease
2025-04-30
EMBARGOED FOR RELEASE
5 PM EDT, APRIL 30
CONTACT: A.J. Hostetler
VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Phone: 804-543-8656 (cell)
Email: AJ.Hostetler@vcuhealth.org
VCU-led research highlights semaglutide’s potential for treating fatty liver disease
International study shows drug reverses liver damage in patients.
RICHMOND, Va. (April 30, 2025) – An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a common liver disease that affects millions worldwide.
Led by Arun Sanyal, M.D., of the Stravitz-Sanyal Institute ...
Does your biological age affect your risk of dementia?
2025-04-30
MINNEAPOLIS — People whose biological age is higher than their chronological age may be more likely to develop dementia than people whose biological age matches or is lower than their chronological age, according to a study published on April 30, 2025, online in Neurology®, the medical journal of the American Academy of Neurology. Biological age is based on biomarkers of aging such as lung function, blood pressure and cholesterol.
The study does not prove that advanced biological age causes dementia; it only shows an association.
“With the rising impact of dementia around the world, identifying risk factors and implementing preventive ...
Research collaboration charts global four-stage evolution of inflammatory bowel disease
2025-04-30
Researchers with the University of Calgary and the Chinese University of Hong Kong (CUHK) led an international collaboration that found inflammatory bowel disease (IBD) progresses through four predictable epidemiological stages as it spreads globally. Published in Nature, the study forecasts a major rise in IBD prevalence in Canada by 2045. Researchers say pinpointing where each region sits on the trajectory gives health-care systems a clear roadmap for anticipating and managing IBD today and in the decades to follow.
“Our analysis draws on a century worth of historical epidemiologic data. The findings enable health authorities ...
Ecological Society of America announces 2025 Fellows
2025-04-30
The Ecological Society of America is pleased to announce its 2025 Fellows. The Society’s fellowship program recognizes the many ways in which its members contribute to ecological research, communication, education, management and policy. This year, the ESA Governing Board has confirmed eight new Fellows and ten new Early Career Fellows.
Fellows are members who have made outstanding contributions to a wide range of fields served by ESA, including, but not restricted to, those that advance or apply ecological knowledge in academics, ...
Critically endangered axolotls bred in captivity appear able to survive release into both artificial and restored Mexican wetlands, but may need specific temperatures to thrive
2025-04-30
Critically endangered axolotls bred in captivity appear able to survive release into both artificial and restored Mexican wetlands, but may need specific temperatures to thrive
Article URL: https://plos.io/3RSL1bu
Article title: Movement ecology of captive-bred axolotls in restored and artificial wetlands: Conservation insights for amphibian reintroductions and translocations
Author countries: Mexico
Funding: This project was funded by UNAM PAPIIT No. 705 IV200117 and IV210117 Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT-IV200117) ...
Tunnel vision during planning can lead us to neglect negative consequences, but this cognitive bias can be addressed by simply prompting people to explicitly consider them
2025-04-30
Tunnel vision during planning can lead us to neglect negative consequences, but this cognitive bias can be addressed by simply prompting people to explicitly consider them
Article URL: https://plos.io/42yZBtL
Article title: Side effects may include: Consequence neglect in generating solutions
Author countries: U.S.
Funding: The author(s) received no specific funding for this work. END ...
2.1 kids per woman might not be enough for population survival
2025-04-30
Human populations need at least 2.7 children per woman – a much higher fertility rate than previously believed – to reliably avoid long-term extinction, according to a new study published April 30, 2025 in the open-access journal PLOS One by Takuya Okabe of Shizuoka University, Japan, and colleagues.
While a fertility rate of 2.1 children per woman is often considered the replacement level needed to sustain a population, this figure doesn’t account for random differences in how many children people have – as well as mortality ...
New “hidden in plain sight” facial and eye biomarkers for tinnitus severity could unlock path to testing treatments
2025-04-30
Researchers at Mass General Brigham have identified new biomarkers for tinnitus by measuring pupil dilation and subtle facial movements that correlate with the level of distress caused by the disorder. Published in Science Translational Medicine, the findings could lead to placebo-controlled treatment studies that have largely been not feasible due to lack of objective measures.
“Imagine if cancer severity were determined by giving patients a questionnaire – this is the state of affairs for some common neurological disorders like tinnitus,” said corresponding author Daniel Polley, ...
“Explainable” AI cracks secret language of sticky proteins
2025-04-30
An AI tool has made a step forward in translating the language proteins use to dictate whether they form sticky clumps similar to those linked to Alzheimer’s Disease and around fifty other types of human disease. In a departure from typical “black-box” AI models, the new tool, CANYA, was designed to be able to explain its decisions, revealing the specific chemical patterns that drive or prevent harmful protein folding.
The discovery, published today in the journal Science Advances, was possible thanks to the largest-ever dataset on protein aggregation created to date. The study gives new insights about the molecular mechanisms underpinning sticky proteins, which are ...